Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AKAMAI TECHNOLOGIES INC insiders sold a net $2.2M of stock across 286 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 10, 2026.
The trade is 3.5% of the 57,197 shares held after it.
2 other insiders sold within 30 days.
445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Marketing Officer Salem-Jackson Kim sold about $257.7K of AKAM under a 10b5-1 plan on Sep 25, 2026; 2 other insiders sold within 30 days and 445 funds added in the latest 13F quarter.
20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 9, 2026.
The trade is 48.0% of the 14,625 shares held after it.
2 other insiders sold within 30 days.
445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and GM Security Sundaram Mani sold about $882.1K of AKAM under a 10b5-1 plan on Sep 25, 2026; 2 other insiders sold within 30 days and 445 funds added in the latest 13F quarter.
25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Jul 15, 2026.
The trade is 10.9% of the 28,472 shares held after it.
2 other insiders sold within 30 days.
445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP - Global Sales Joseph Paul C sold about $327.5K of AKAM under a 10b5-1 plan on Sep 15, 2026; 2 other insiders sold within 30 days and 445 funds added in the latest 13F quarter.
24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Mar 16, 2026.
The trade is 9.8% of the 31,572 shares held after it.
1 other insider sold within 30 days.
445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP - Global Sales Joseph Paul C sold about $393.0K of AKAM on Jul 15, 2026; 1 other insider sold within 30 days and 445 funds added in the latest 13F quarter.
26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Feb 13, 2026.
The trade is 0.8% of the 31,006 shares held after it.
2 other insiders sold within 30 days.
445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Blumofe Robert sold about $31.4K of AKAM on Jun 18, 2026; 2 other insiders sold within 30 days and 445 funds added in the latest 13F quarter.
286 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Dr. Leighton
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$16.0M
$12.4M
$6.2M
-17%
+158%
2024
$15.1M
$1.7M
$5.5M
-9%
+108%
2023
$13.4M
$26.2M
$5.1M
+13%
+52%
2022
$12.0M
$3.5M
$4.4M
-20%
-3%
2021
$12.0M
$15.7M
$4.3M
+11%
+35%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.2M sold by insiders over 180 days, 445 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $1.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AKAM
FY Dec 2025
$4.2B
FY Dec 2024
$4.0B
FY Dec 2023
$3.8B
FY Dec 2022
$3.6B
FY Dec 2021
$3.5B
Jun 2026
$1.1B
Mar 2026
$1.1B
Dec 2025
$1.1B
Sep 2025
$1.1B
Jun 2025
$1.0B
Mar 2025
$1.0B
Dec 2024
$1.0B
Sep 2024
$1.0B
At each fiscal year end
Single quarter
Net margin, TTM
+9.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AKAM
FY Dec 2025
+10.7%
FY Dec 2024
+12.7%
FY Dec 2023
+14.4%
FY Dec 2022
+14.5%
FY Dec 2021
+18.8%
Jun 2026
+7.2%
Mar 2026
+9.9%
Dec 2025
+7.8%
Sep 2025
+13.3%
Jun 2025
+9.9%
Mar 2025
+12.1%
Dec 2024
+13.7%
Sep 2024
+5.8%
At each fiscal year end
Single quarter
Free cash flow, TTM
$956.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AKAM
FY Dec 2025
$1.0B
FY Dec 2024
$1.1B
FY Dec 2023
$890.5M
FY Dec 2022
$1.0B
FY Dec 2021
$1.1B
Jun 2026
$181.3M
Mar 2026
$210.8M
Dec 2025
$234.9M
Sep 2025
$329.1M
Jun 2025
$313.6M
Mar 2025
$133.4M
Dec 2024
$250.9M
Sep 2024
$279.7M
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity AKAM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt AKAM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+8.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AKAM
FY Dec 2025
+9.2%
FY Dec 2024
+10.7%
FY Dec 2023
+12.2%
FY Dec 2022
+11.8%
FY Dec 2021
+14.8%
Jun 2026
+8.9%
Mar 2026
+9.2%
Dec 2025
+9.2%
Sep 2025
+10.6%
Jun 2025
+9.2%
Mar 2025
+9.8%
Dec 2024
+10.7%
Sep 2024
+11.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AKAM
FY Dec 2025
+4.1%
FY Dec 2024
+5.0%
FY Dec 2023
+6.0%
FY Dec 2022
+6.4%
FY Dec 2021
+8.2%
Jun 2026
+3.2%
Mar 2026
+4.0%
Dec 2025
+4.1%
Sep 2025
+4.8%
Jun 2025
+4.1%
Mar 2025
+4.5%
Dec 2024
+5.0%
Sep 2024
+5.3%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital AKAM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+4.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AKAM
FY Dec 2025
+6.0%
FY Dec 2024
+6.2%
FY Dec 2023
+7.7%
FY Dec 2022
+9.1%
FY Dec 2021
+10.9%
Jun 2026
+4.2%
Mar 2026
+5.7%
Dec 2025
+6.0%
Sep 2025
+6.9%
Jun 2025
+5.9%
Mar 2025
+6.1%
Dec 2024
+6.2%
Sep 2024
+6.7%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
35.95x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AKAM
FY Dec 2025
28.42x
FY Dec 2024
29.34x
FY Dec 2023
33.62x
FY Dec 2022
25.78x
FY Dec 2021
29.78x
Jun 2026
42.68x
Mar 2026
38.80x
Dec 2025
28.42x
Sep 2025
22.22x
Jun 2025
28.28x
Mar 2025
27.10x
Dec 2024
29.34x
Sep 2024
29.96x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value AKAM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield AKAM
FY Dec 2025
+8.1%
FY Dec 2024
+7.9%
FY Dec 2023
+5.0%
FY Dec 2022
+7.8%
FY Dec 2021
+5.7%
Jun 2026
+5.6%
Mar 2026
+6.5%
Dec 2025
+8.1%
Sep 2025
+9.5%
Jun 2025
+8.4%
Mar 2025
+8.3%
Dec 2024
+7.9%
Sep 2024
+7.8%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -2%, PEG needs growth
PEG, trailing AKAM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
4.40x
FY Dec 2022
n/a
FY Dec 2021
1.76x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
18.72x
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
19.89x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
AKAM ranks highest on growth (75th percentile) and profitability (54th), and lowest on risk and compliance (12th), among Services peers.
Profitability
54
Inputs
Return on equity+8.9% · 55 pct, sector of 207
Return on assets+3.2% · 62 pct, sector of 269
Return on invested capitalno debt line filed
Return on capital employed+4.2% · 46 pct, sector of 203
Growth
75
Inputs
Revenue growth, YoY+5.4% · 51 pct, sector of 341
Backlog growth, YoY+76.7% · 99 pct, sector of 77
Insider conviction
23
Inputs
Net Form 4 buying (codes P and S), 180d-$736K · 45 pct, sector of 174
Insider buyers, 180d0 · 0 pct, sector of 179
Institutional and government
52
Inputs
Funds adding, latest quarter445 · 93 pct, sector of 243
Congress net buyers, 365d0 · 56 pct, sector of 37
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$60K · 7 pct, sector of 61
Risk and compliance
12
Inputs
Short interest, % of float+13.7% · 9 pct, sector of 383
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+23.5% · 15 pct, sector of 227
2 not measured: Financial health, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AKAM filings, in plain words
Are Akamai Technologies insiders buying or selling AKAM?
In the 180 days to 2026-10-27, Akamai Technologies insiders were net sellers, a net $2.2M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded AKAM?
Yes. In the year to 2026-10-27, 1 House member disclosed buying AKAM and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.
Are there planned insider sales of AKAM?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.1M of stock; the latest, by Salem-Jackson Kim, was filed 2026-09-25.
Read the full summary
In the 180 days to 2026-10-27, Akamai Technologies insiders were net sellers of AKAM, a net $2.2M across purchases and sales reported on Form 4 by 4 sellers. 50% of the 6 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying AKAM and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.